The antibody targets the C‐terminus novel sequence of all mutant CALR variants in MPN and CD3 on T cells, thus engaging CD8 T cells into killing cells that expose on the cell‐surface the mutated CALR tumour antigen. Here, CD8A is linked to neoplasm.